Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Last trade$315.72
Day change+$5.00 (+1.61%)
Day range$306.58 – $319.25
Volume2,517,607
Market cap$118.29B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$118.29B
Price / earnings
32.65×
Price / book
5.04×
Price / sales
4.5×
EV / sales
4.94×
EV / EBITDA
18.72×
Profitability
Earnings per share
$9.52
Return on assets
7.67%
Return on equity
15.45%
Dividend yield
1.13%
Liquidity and leverage
Debt / equity
0.64×
Current ratio
2.18×
Quick ratio
1.3×
Cash ratio
0.5×
Cash flow
Price / cash flow
21.72×
Price / free cash flow
25.87×
Free cash flow
$4.57B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SYK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$6.52B
$6.59B
$6.02B
$7.17B
$6.06B
$6.02B
$5.87B
$6.44B
Cost of revenue
$2.27B
$2.09B
$2.21B
$2.54B
$2.21B
$2.18B
$2.12B
$2.26B
Gross profit
$4.25B
$4.5B
$3.81B
$4.63B
$3.85B
$3.84B
$3.74B
$4.17B
Selling, general and administrative
$2.31B
$2.23B
$2.28B
$2.23B
$2.05B
$2.08B
$2.3B
$2.12B
Research and development
$433M
$434M
$413M
$401M
$410M
$407M
$405M
$358M
Total operating expenses
$3.21B
$2.84B
$2.87B
$2.82B
$2.72B
$2.73B
$2.91B
$3.59B
Operating income
$1.03B
$1.66B
$936M
$1.8B
$1.14B
$1.11B
$837M
$581M
Interest expense
-$143M
-$141M
-$148M
-$607M
-$157M
-$159M
-$137M
-$409M
Income before taxes
$997M
$1.56B
$850M
$1.71B
$1.03B
$1.02B
$764M
$528M
Income taxes
$244M
$288M
$105M
$856M
$170M
$132M
$110M
-$18M
Net income
$753M
$1.28B
$745M
$849M
$859M
$884M
$654M
$546M
Net income attributable to common shareholders
$753M
$1.28B
$745M
$849M
$859M
$884M
$654M
$546M
EBITDA
$1.62B
$1.96B
$1.24B
$2.13B
$1.52B
$1.46B
$1.14B
$1.8B
Basic earnings per share
$1.97
$3.32
$1.95
$2.22
$2.25
$2.32
$1.71
$1.43
Diluted earnings per share
$1.96
$3.30
$1.93
$2.20
$2.22
$2.29
$1.69
$1.41
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.
In a comparison of two Medical-Products sector stocks, GE HealthCare Technologies (GEHC) emerges as the better value option compared to Stryker (SYK). GEHC has a Zacks Rank of #2 (Buy) with stronger earnings estimate revisions, a lower forward P/E ratio of 16.53 versus SYK's 20.86, and a superior Value grade of B compared to SYK's D grade. GEHC also shows better valuation metrics across PEG and P/B ratios.
Stryker Corporation (SYK) is experiencing elevated implied volatility in its options market, particularly in December 2026 put options. However, the fundamental outlook appears weak, with the company holding a Zacks Rank #4 (Sell) rating and six analysts downgrading earnings estimates for the current quarter, reducing consensus estimates from $5.10 to $5.03 per share.
Medtronic completed a spinoff of its diabetes segment (MiniMed) and retired 55 million shares without cash expenditure, which will boost future EPS. The company reported strong Q1 FY2027 results with 14% revenue growth and is approaching Dividend King status (49 consecutive years of increases). Despite operational improvements and a reinvigorated pipeline with 50+ FDA approvals, Medtronic trades at a discount to medtech peers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 30, 2026
$0.88
Oct 30, 2026
recurring
Jun 30, 2026
$0.88
Jul 31, 2026
recurring
Mar 31, 2026
$0.88
Apr 30, 2026
recurring
Dec 31, 2025
$0.88
Jan 30, 2026
recurring
Sep 30, 2025
$0.84
Oct 31, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.